“…Based on these analyses, phase II/III studies investigating the role of ASCT and alloSCT started treatment with 4–6 courses of CHOEP (d'Amore et al , ), and recent reviews (Moskowitz et al , ) as well as current National Comprehensive Cancer Network NHL guidelines (https://www.nccn.org/professionals/physician_gls/f_guidelines_nojava.asp), European Society for Medical Oncology (d'Amore et al , ) and German/Austrian guidelines (Hopfinger et al , ) mention CHOEP as a (preferable) alternative to CHOP in younger patients treated with curative intent. Chemotherapy consisting of CHOP plus etoposide and gemcitabine (CHOP‐EG) (Kim et al , ), cisplatin, etoposide, gemcitabine and methylprednisolone (PEGS) (Mahadevan et al , ), cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternating with pralatrexate (P) (Advani et al , ) as well as intense regimens like hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone (Hyper‐CVAD) (Escalon et al , ) failed to convincingly improve outcomes (Table ). Phase III studies combining CHOP with antibodies, antibody‐drug conjugates (BV), or histone deacetylase (HDAC)‐inhibitors (Ro‐CHOP) and comparing the experimental arm to CHOP are ongoing (NCT 01796002).…”